{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:23Z","timestamp":1792791923099,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among 994 patients with essential thrombocythemia (ET) who were genotyped for the MPLW515L\/K mutation, 30 patients carrying the mutation were identified (3.0%), 8 of whom also displayed the JAK2V671F mutation. MPLW515L\/K patients presented lower hemoglobin levels and higher platelet counts than did wild type (wt) MPL; these differences were highly significant compared with MPLwt\/JAK2V617F\u2013positive patients. Reduced hemoglobin and increased platelet levels were preferentially associated with the W515L and W515K alleles, respectively. MPL mutation was a significant risk factor for microvessel disturbances, suggesting platelet hyperreactivity associated with constitutively active MPL; arterial thromboses were increased only in comparison to MPLwt\/JAK2wt patients. MPLW515L\/K patients presented reduced total and erythroid bone marrow cellularity, whereas the numbers of megakaryocytes, megakaryocytic clusters, and small-sized megakaryocytes were all significantly increased. These data indicate that MPLW515L\/K mutations do not define a distinct phenotype in ET, although some differences depended on the JAK2V617F mutational status of the counterpart.<\/jats:p>","DOI":"10.1182\/blood-2008-01-135897","type":"journal-article","created":{"date-parts":[[2008,6,2]],"date-time":"2008-06-02T21:02:07Z","timestamp":1212440527000},"page":"844-847","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":192,"title":["Characteristics and clinical correlates of MPL 515W&gt;L\/K mutation in essential thrombocythemia"],"prefix":"10.1182","volume":"112","author":[{"given":"Alessandro M.","family":"Vannucchi","sequence":"first","affiliation":[{"name":"Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico-Chirurgica, Universit\u00e0 degli Studi, Firenze;"},{"name":"Istituto Toscano Tumori, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[{"name":"Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico-Chirurgica, Universit\u00e0 degli Studi, Firenze;"},{"name":"Istituto Toscano Tumori, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico-Chirurgica, Universit\u00e0 degli Studi, Firenze;"},{"name":"Istituto Toscano Tumori, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pancrazzi","sequence":"additional","affiliation":[{"name":"Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico-Chirurgica, Universit\u00e0 degli Studi, Firenze;"},{"name":"Istituto Toscano Tumori, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Guerini","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia, Ospedali Riuniti, Bergamo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Laboratorio di Epidemiologia Clinica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Dipartimento di Ematologia e Centro per l'Emofilia e la Trombosi, Ospedale San Bortolo, Vicenza;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[{"name":"Dipartimento di Ematologia, Universit\u00e0 degli Studi, Bari;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lo-Coco","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Diagnostica per Immagini, Universit\u00e0 Tor Vergata, Roma; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Delaini","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia, Ospedali Riuniti, Bergamo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Villani","sequence":"additional","affiliation":[{"name":"Laboratorio di Epidemiologia Clinica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Finotto","sequence":"additional","affiliation":[{"name":"Dipartimento di Ematologia e Centro per l'Emofilia e la Trombosi, Ospedale San Bortolo, Vicenza;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ammatuna","sequence":"additional","affiliation":[{"name":"Dipartimento di Biopatologia e Diagnostica per Immagini, Universit\u00e0 Tor Vergata, Roma; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Alterini","sequence":"additional","affiliation":[{"name":"Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico-Chirurgica, Universit\u00e0 degli Studi, Firenze;"},{"name":"Istituto Toscano Tumori, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Carrai","sequence":"additional","affiliation":[{"name":"Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico-Chirurgica, Universit\u00e0 degli Studi, Firenze;"},{"name":"Istituto Toscano Tumori, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Capaccioli","sequence":"additional","affiliation":[{"name":"Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico-Chirurgica, Universit\u00e0 degli Studi, Firenze;"},{"name":"Istituto Toscano Tumori, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta Di","family":"Lollo","sequence":"additional","affiliation":[{"name":"Dipartimento di Oncologia, Universit\u00e0 degli Studi, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Liso","sequence":"additional","affiliation":[{"name":"Dipartimento di Ematologia, Universit\u00e0 degli Studi, Bari;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia, Ospedali Riuniti, Bergamo,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[{"name":"Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico-Chirurgica, Universit\u00e0 degli Studi, Firenze;"},{"name":"Istituto Toscano Tumori, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia, Ospedali Riuniti, Bergamo,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111722003981700_B1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2019111722003981700_B2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2019111722003981700_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111722003981700_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111722003981700_B5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia.","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"2019111722003981700_B6","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"2019111722003981700_B7","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"2019111722003981700_B8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111722003981700_B9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"2019111722003981700_B10","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"2019111722003981700_B11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111722003981700_B12","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"2019111722003981700_B13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"2019111722003981700_B14","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"2019111722003981700_B15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","article-title":"Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.","volume":"135","author":"Lasho","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111722003981700_B16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111722003981700_B17","doi-asserted-by":"crossref","unstructured":"Pikman\n              Y\n            \n            \n              Lee\n              BH\n            \n            \n              Mercher\n              T\n            \n            \n          \n          MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.\n          PLoS Med\n          2006\n          3\n          e270\n          \n            http:\/\/medicine.plosjournals.org\/","DOI":"10.1371\/journal.pmed.0030270"},{"key":"2019111722003981700_B18","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms.","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2019111722003981700_B19","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"2019111722003981700_B20","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years.","volume":"123","author":"Policitemia","year":"1995","journal-title":"Ann Intern Med"},{"key":"2019111722003981700_B21","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111722003981700_B22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment.","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"2019111722003981700_B23","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"key":"2019111722003981700_B24","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden.","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"2019111722003981700_B25","article-title":"A sensitive detection method for MPLW515L or W515K mutation in chronic myeloproliferative disorders with LNA-modified probes and real time PCR.","author":"Pancrazzi","journal-title":"J Mol Diagn"},{"key":"2019111722003981700_B26","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity.","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"2019111722003981700_B27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF02982575","article-title":"Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).","volume":"76","author":"Michiels","year":"2002","journal-title":"Int J Hematol"},{"key":"2019111722003981700_B28","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis.","volume":"110","author":"Chalign\u00e9","year":"2007","journal-title":"Blood"},{"key":"2019111722003981700_B29","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","article-title":"Extending JAK2V617F and MPLW515 mutation analysis to single hematopoietic colonies and B- and T-lymphocytes.","volume":"25","author":"Pardanani","year":"2007","journal-title":"Stem Cells"},{"key":"2019111722003981700_B30","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2005-06-2600","article-title":"An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.","volume":"107","author":"Staerk","year":"2006","journal-title":"Blood"},{"key":"2019111722003981700_B31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2006-939442","article-title":"Thrombopoietin and platelet function.","volume":"32","author":"Akkerman","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2019111722003981700_B32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2141.1997.802720.x","article-title":"Influence of thrombopoietin on platelet activation in myeloproliferative disorders.","volume":"97","author":"Usuki","year":"1997","journal-title":"Br J Haematol"},{"key":"2019111722003981700_B33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"2019111722003981700_B34","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.","volume":"35","author":"Williams","year":"2007","journal-title":"Exp Hematol"},{"key":"2019111722003981700_B35","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/3\/844\/1306513\/zh801508000844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/3\/844\/1306513\/zh801508000844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T22:00:51Z","timestamp":1574028051000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/3\/844\/25317\/Characteristics-and-clinical-correlates-of-MPL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-01-135897","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}